288 related articles for article (PubMed ID: 18096230)
1. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).
Bexborn F; Andersson PO; Chen H; Nilsson B; Ekdahl KN
Mol Immunol; 2008 Apr; 45(8):2370-9. PubMed ID: 18096230
[TBL] [Abstract][Full Text] [Related]
2. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
[TBL] [Abstract][Full Text] [Related]
4. Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.
Daha MR; Deelder AM; Van Es LA
J Immunol; 1984 May; 132(5):2538-42. PubMed ID: 6232321
[TBL] [Abstract][Full Text] [Related]
5. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
6. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase.
Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2009 Jan; 106(3):882-7. PubMed ID: 19136636
[TBL] [Abstract][Full Text] [Related]
7. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
[TBL] [Abstract][Full Text] [Related]
8. Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase.
Ponnuraj K; Xu Y; Macon K; Moore D; Volanakis JE; Narayana SV
Mol Cell; 2004 Apr; 14(1):17-28. PubMed ID: 15068800
[TBL] [Abstract][Full Text] [Related]
9. Detection of Complement Factor B Autoantibodies by ELISA.
Józsi M; Uzonyi B
Methods Mol Biol; 2021; 2227():141-145. PubMed ID: 33847939
[TBL] [Abstract][Full Text] [Related]
10. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors.
Paixão-Cavalcante D; Torreira E; Lindorfer MA; Rodriguez de Cordoba S; Morgan BP; Taylor RP; Llorca O; Harris CL
J Immunol; 2014 May; 192(10):4844-51. PubMed ID: 24729617
[TBL] [Abstract][Full Text] [Related]
11. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
[TBL] [Abstract][Full Text] [Related]
12. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
Harris CL; Pettigrew DM; Lea SM; Morgan BP
J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
[TBL] [Abstract][Full Text] [Related]
13. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
Pryzdial EL; Isenman DE
J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
[TBL] [Abstract][Full Text] [Related]
14. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
15. Decay acceleration of the complement alternative pathway C3 convertase.
Hourcade DE; Mitchell LM; Medof ME
Immunopharmacology; 1999 May; 42(1-3):167-73. PubMed ID: 10408377
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effect of factor J on the alternative complement pathway.
González-Rubio C; Jiménez-Clavero MA; Fontán G; López-Trascasa M
J Biol Chem; 1994 Oct; 269(42):26017-24. PubMed ID: 7929312
[TBL] [Abstract][Full Text] [Related]
17. C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme.
Rawal N; Pangburn MK
J Biol Chem; 1998 Jul; 273(27):16828-35. PubMed ID: 9642242
[TBL] [Abstract][Full Text] [Related]
18. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
19. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
20. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.
Pangburn MK; Müller-Eberhard HJ
Biochem J; 1986 May; 235(3):723-30. PubMed ID: 3638964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
